Breaking News Headlines Today | Ground News

See every side of every news story

curetoday.com image

News from curetoday.com

We’ve assigned a media bias rating of unknown to curetoday.com. You can read more about our methodology here.

curetoday.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about curetoday.com

Where is curetoday.com located?curetoday.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top curetoday.com News

Trispecific Antibody Earns FDA Fast Track Designation in Multiple Myeloma

San Francisco, California · San Francisco

Trispecific Antibody Earns FDA Fast Track Designation in Multiple Myeloma

82% Center coverage: 11 sources

Investigators are currently assessing IBI3003 among patients with relapsed/refractory multiple myeloma in a phase 1/2 trial.See the Story

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

United States · United States

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

42% Center coverage: 7 sources

/PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and...See the Story

FDA Clears Larger Vial Size of Nelarabine Injection in T-ALL and T-LBL | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

United States · United States

FDA Clears Larger Vial Size of Nelarabine Injection in T-ALL and T-LBL | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

The FDA approves a larger vial of nelarabine injection, enhancing treatment flexibility for T-cell leukemia in adults and children.See the Story

Breaking News Topics Related to curetoday.com